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Summary 
Background. Topical administration of ketoprofen to treat local subcutaneous pain 
significantly reduces gastrointestinal and cardiovascular adverse effects associated 
with oral delivery. However, this benefit must be weighed against the risk of 
photosensitisation/phototoxicity. Objective. To substantiate the safety and efficacy of 
topical ketoprofen delivery from a patch. Methods. Experiments were performed, and 
published information analysed, (a) to confirm the superior skin permeability and 
pharmacological activity of ketoprofen, and (b) to demonstrate the lower incidence of 
ketoprofen photosensitisation/phototoxicity when delivered from a topical patch.  
Results. Ketoprofen’s photodegradation products were more photoallergic than the 
drug itself.  The period post-ketoprofen treatment that skin should be protected from 
UV radiation (while the drug is cleared from the application site) was estimated. 
Conclusions. Photosensitisation to ketoprofen can be mitigated by a patch 
formulation, which protects the drug from direct UV exposure during skin application, 
and reduces the formation of even more photoallergic photodegradation products. 
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Introduction 
 The application of drugs to the skin is typically associated with two 
therapeutic objectives: (a) to deliver the active into the skin to treat dermatologic 
disease (often referred to as “topical” delivery), or (b) to deliver the compound 
through the skin and into the systemic circulation to achieve a central effect (so-
called “transdermal” drug delivery) [1, 2]. The former usually involves classic, topical 
formulations, such as creams, gels and ointments, while the latter is accomplished 
most commonly with an adhesive patch that may be able to sustain drug delivery 
over a period of up to one week. 
 Increasingly, though, drug administration to the skin is being used to relieve 
the pain associated with local, subcutaneous inflammation in joints and muscles, a 
goal which is distinct from those of topical and transdermal delivery [3]. In Asia, 
there is an established and very large market for a variety of products, particularly 
flexible, medicated patches, which deliver several non-steroidal anti-inflammatory 
drugs (NSAIDs) for this purpose.  Elsewhere, despite a much smaller (but now 
growing) commercial interest, there are nevertheless many gel formulations available 
both on prescription and over-the-counter. 
 The rationale underpinning these products is that NSAID delivery from the 
“outside-in”, through the skin and into the subcutaneous compartment, is at least as 
efficient from a therapeutic standpoint as “inside-out” oral therapy [4, 5]. 
Importantly, and in addition, the former, percutaneous approach results in 
significantly lower systemic exposure of the patient to the NSAID and essentially 
eliminates the majority of drug-related adverse effects, such as gastrointestinal 
disturbances, and cardiovascular disorders (Table 1) [6]. 
Nonetheless, there are other safety issues, which arise with topical NSAID 
delivery.  In the case of ketoprofen, the specific drug of interest in this work, it is 
well-known that its topical application can cause photocontact dermatitis (PCD) [7-
10], and that this has limited its use in certain parts of the world [11]. Recent 
statistics on the frequency of PCD [12-14] based on spontaneous adverse drug 
reaction reports, indicate that the use of a topical patch product results in an 
apparently smaller incidence of photoallergy relative to that observed when the drug 
is delivered from a conventional topical gel (Table 2).  While the under-reporting of 
ketoprofen-induced PCD has been highlighted, and remains a concern [9], it seems 
nonetheless reasonable to anticipate that the woven cloth backing of the topical 
patch blocks, at least in part, the interaction of UV radiation with the drug and the 
creation of potentially more sensitising photo-degradation products.  The objective of 
this paper is to explore this thesis in more detail and to provide supporting evidence 
for the potential benefits of delivering ketoprofen from a topical patch. 
Methods 
1. Pharmacokinetics of ketoprofen (KP) in vivo in man following oral dosing and 
topical delivery from either a patch or a gel 
Healthy male volunteers were dosed with ketoprofen via: (a) oral administration of 
either a standard tablet containing 100 mg (Orudis [15], n = 7) or a sustained 
release (SR) formulation of 150 mg (Orudis SR 150 [16], n = 8); (b) topical 
application over 24 hours of either a patch (Mohrus Tape, 20 mg, 70 cm2, n = 6) or a 
gel (Sector gel [17], 300 mg, 900 cm2, n = 5). Serum samples were obtained post-
administration up to a maximum 72 hours at a frequency sufficient to obtain 
accurate estimates of Cmax and AUC0∞). 
2. Photodegradation products of KP in topical formulations 
A KP-containing patch (KEPLAT (Hisamitsu Pharmaceutical Co., Inc., Japan); 20 mg 
of drug/70 cm2 was exposed to sunlight striking the backing surface. A KP gel  
(Profenid, Sanofi, France) was applied at a dose of 0.8 mg of drug in 20 mg of 
formulation over 70 cm2 of a polyethylene terephthalate film and was exposed to 
sunlight. Control experiments involved the same exposure conditions with the 
delivery systems completely covered by aluminum foil. The cumulative amount of 
ultraviolet light exposure (i.e., natural sunlight in Japan during January) over an 8-
hour period was 15 W.hr/m2 (5.41 J/cm2). Post-exposure, the drug and any 
photodegradation products were extracted from the patch with tetrahydrofuran 
(shaking for 30 minutes with 50 mL of the solvent).  2 mL of this extract was diluted 
to 100 mL with methanol, and 15 µL of this solution was analysed by HPLC 
(Shimadzu-XR, Shimadzu Corp., Kyoto, Japan) with UV detection (254 nm) using a 
silica-based reversed phase column (TSK-gel ODS-120T, Tosoh Corp., Tokyo, Japan), 
and a mobile phase comprising a 1:1 v/v mixture of 0.1% acetic acid and acetonitrile. 
The same procedure was adopted for extracting drug and any photodegradation 
products from the gel, except that the extraction solvent, in this case, was a 1:1 v/v 
mixture of water and methanol.  
3. Photosensitisation potential of KP and its photodegradation products 
Photosensitisation and photochallenge of female guinea pigs (Hartley, Japan 
Laboratory Animals Inc. Tokyo, Japan; n = 8 for the irradiated group, n = 10 for the 
control, non-irradiated animals) were conducted using a modified version of the 
adjuvant and tape-strip method described previously [18]. On day 0, 0.1 mL of an 
emulsified 1:1 v/v mixture of Freund’s complete adjuvant (Wako Pure Chemical 
Industries, Ltd., Japan) and saline was injected subcutaneously at each of the 4 
corners of an 8 cm2 area of the animal’s neck (the hair at this region having been 
clipped carefully in advance). After stripping the stratum corneum with adhesive tape 
(CELLOTAPE, Nichiban Co., Ltd. Tokyo, Japan) approximately 20 times, 1mL of an 
8% w/v solution of KP, or of one of its photodegradation products (3-(1-hydroxy) 
ethyl benzophenone (KP-OH), 3-acetyl benzophenone (Ac-KP) and 3-ethyl 
benzophenone (KP-Et)), was applied and irradiated with UVA at 10 J/cm2.  The time 
of exposure to the drug or its photodegradation products was 4 hours. The 
procedure was repeated once daily for 5 consecutive days. On day 21 post-initiation 
of the experiment, 20 µL of 0.5%, 2% and 8% w/v solutions of KP, Et-KP, KP-OH 
and Ac-KP, were separately applied to 2.25 cm2 of dorsal skin (again, pre-clipped) 
and irradiated with 10 J/cm2 UVA.  The exposure time to the chemicals was 4 hours. 
Skin reactions at the photochallenged sites were graded at 24 and 48 h after UVA 
irradiation, using a Draize scale [19]. 
4. Photoallergic responses in guinea pig and mouse following topical exposure to a 
ketoprofen patch and a ketoprofen gel 
In guinea pigs, exactly the same procedure as described above was followed except 
that (a) the sensitisation phase involved exposure to either 8 cm2 of a KP patch 
(KEPLAT, Hisamitsu Pharmaceutical Co., Inc., Japan)) or 90 mg of a KP gel (Ketum, 
Menarini, Italy), and (b) the challenge phase involved exposure of the animal’s back 
skin to either 4 cm2 of the patch or 45 mg of the gel. The patch areas and quantities 
of gel applied ensured that equivalents amounts of ketoprofen were administered by 
the two dosage forms. 
To evaluate photosensitivity in mice, a modified local lymph node assay (LLNA) was 
employed [20]. Female mice (BALB/c, Japan SLC, Inc. Hamamatsu, Japan) were 
treated with either 1 cm2 of a KP patch (KEPLAT) or 11.4 mg/cm2 of a KP gel 
(Ketum) on both sides of each ear, and irradiated with 40 J/cm2 of UVA (3.1 
mW/cm2, 3.5 hours) during the application. After the irradiation, the KP formulations 
were removed (application time was 4 hours). Photosensitization was then 
performed on three consecutive days, with the mice being additionally irradiated with 
40 J/cm2 of UVA after formulation on the third day. On the fifth day after initiation of 
the experiment, the mice were injected intravenously with 250 µL of phosphate-
buffered saline at pH 7.4 (PBS) containing 20 µCi [methyl-3H] thymidine (3HTdR, 
Moravek Biochemicals, USA). Mice were sacrificed 5 hours later, and the draining 
auricular lymph nodes were excised. Single cell suspensions of lymph node cells 
(LNC) were prepared by gentle mechanical disaggregation. LNC were centrifuged at 
1100 rpm for 10 minutes, washed twice with 3 mL of PBS and re-suspended with 3 
mL of 5% v/v trichloroacetic acid (TCA). After overnight incubation at 4˚C, the 
precipitate was recovered by centrifugation, re-suspended with 1 mL of 5% TCA and 
transferred into 10 mL of scintillation fluid. 3HTdR incorporation was measured by 
scintillation counting (Hitachi Aloka Medical, Ltd., Tokyo, Japan). Statistical analysis 
was performed using a Tukey type multiple comparison and SAS software (SAS 
Institute Japan Ltd, Tokyo, Japan). 
5. Skin concentration of KP in human patients after topical application of a patch 
The ketoprofen patch (Mohrus Tape, Hisamitsu Pharmaceutical Co., Inc., Japan)) 
was applied to 14 patients with osteoarthritis or other orthopaedic disease prior to 
arthrocentesis or a similar procedure. After removal of patch, arthritic lesion tissues 
were obtained and stored in a freezer until analysis. The local skin concentration of 
ketoprofen was measured as follows. About 200 mg of skin was minced and 
homogenized in methanol. The filtered liquid was evaporated, re-dissolved in acidic 
solution and extracted with ethyl ether.  The organic phase was evaporated and the 
residue was methylated with ethereal diazomethane. Once the methylated KP had 
been separated using TLC, it was quantified by gas chromatography-mass 
spectrometry (gas chromatograph: HP 5890 Series II Gas Chromatograph (Hewlett 
Packard, Waldbronn, Germany); mass spectrometer: JMS SX102A (JEOL Ltd, Tokyo, 
Japan); column: J&W DB-17 (15 m x 0.25 mm, 0.25 µm, Agilent Technologies, Inc, 
CA, USA)). 
 
Results & Discussion 
1. Establishing the efficacy of topical ketoprofen delivery 
 Figure 1 illustrates the impact of administration route on two key 
pharmacokinetic parameters (maximum plasma concentration (Cmax) and area under 
the plasma concentration versus time profile (AUC0∞)) for ketoprofen in man.  
Notably, Cmax is 10-100 times higher after systemic administration (oral [15, 16]) 
compared to that achieved following topical application of a patch or a gel [17]. 
 There are obviously many NSAIDs available for topical delivery to the 
subcutaneous compartment and the selection of an appropriate candidate must take 
into account both the potency of the drug and its ability to be absorbed to the site of 
action.  It is self-evident, therefore, that even a compound with sub-nanomolar 
potency at the target receptor is never going to be a useful drug unless it is capable 
of penetrating the skin.  
 Information in the literature enables this evaluation to be performed with 
relative ease and the data available on NSAID skin permeability in man [21], COX 
inhibition in vitro [22], and anti-inflammatory activity in vivo in rats [23], identify 
ketoprofen as a clear ‘lead’ for topical delivery to achieve an anti-inflammatory effect. 
Furthermore, a pivotal pharmacokinetic study in patients scheduled for knee surgery 
has demonstrated that a topical patch formulation (Mohrus Tape) is able to achieve 
equivalent concentrations in subcutaneous tissue compartments, such as muscle and 
tendon, as those measured after oral administration of the drug [24] (Figure 2A); 
however, as previously discussed, the systemic exposure to ketoprofen (as measured 
by the plasma concentration) when delivered transdermally is significantly smaller, 
by more than two orders of magnitude, relative to that following oral dosing.  In 
addition, the temporal evolution of ketoprofen concentrations in muscle and tendon 
are similar, yet noticeably different from that in plasma, providing additional 
evidence that the drug is reaching these subcutaneous targets from “outside-in”, and 
not via redistribution from the central compartment (Figure 2B) [24]. 
2. Safety issues associated with topical ketoprofen delivery 
 Table 3 shows the effect of UVA irradiation (5.41 J/cm2) on ketoprofen in 
topical gel (Ketum) and patch (KEPLAT) products.  The woven cloth backing of the 
topical patch clearly prevented the UVA light from interacting with the drug to form 
some of its principal photodegradation products, 3-(1-hydroxy) ethyl benzophenone 
(KP-OH), 3-acetyl benzophenone (Ac-KP) and 3-ethyl benzophenone (KP-Et), the 
structures of which are shown in the Table 3.  In contrast, the drug in the gel was 
significantly degraded, such that less than 20% of the original quantity was 
ultimately recoverable. 
 To confirm the relevance of the above findings, a photosensitisation assay 
[18] was performed in guinea pigs comparing ketoprofen with the three 
photodegradation products identified in Table 3. The results were expressed in terms 
of an overall score, which reflected the sum of two skin reactions (i.e., erythema and 
edema) using Draize test criteria [19], and are summarised in Table 4.  The data 
reflect a dose-dependent response to ketoprofen, Ac-KP and Et-KP (but less 
obviously to KP-OH for as yet unknown reason); in addition, it is clear that KP-OH 
and Et-KP are stronger photoallergens, suggesting (in line with the information in 
Table 3) that the risk of photosensitisation from a topical ketoprofen gel is greater 
than that from a topical patch.  At present, there is no reason to suspect that the 
ketoprofen photoproducts have any potential to induce T-cell response in the 
absence of UVA radiation. 
 A further photosensitisation test was performed in guinea pigs that had been 
treated with either a topical ketoprofen gel (Ketum) or a topical patch (KEPLAT) 
containing the drug (Table 5).  At 24 and 48 hours post-challenge, the average 
sensitisation scores (determined in the same way as the experiments summarised in 
Table 4) at the gel-treated sites were significantly higher than those at the sites to 
which the topical patch had been applied, confirming the conclusions deduced 
before. 
 Finally, a photo local lymph node assay (photo LLNA, a modified form of the 
well-known LLNA [20]) was performed in mice.  In this experiment, the extent of 
photosensitisation is determined by the uptake of 3H-thymidine and the results are 
presented in Figure 3.  The photoallergic response after treatment with ketoprofen 
gel was significantly greater (P < 0.001) than that either (i) following treatment with 
the patch, or (ii) subsequent to the no-treatment control.  In contrast, patch and 
control results were not significantly different. 
3. Mitigating the risk of residual ketoprofen in skin post-treatment 
 The analysis of the collective data presented above fully supports the selection 
of ketoprofen as a suitable NSAID candidate to treat subcutaneous inflammation, 
and that a topical patch formulation of the drug has significant advantages over a 
conventional gel with respect to the likely incidence of photocontact dermatitis.  
However, while the woven cloth backing of the patch clearly blocks skin irradiation 
while in place on the skin, it has no such effect once removed.  Consequently, 
because dermal drug clearance is principally controlled by slow percutaneous 
diffusion [25], there remains an important risk that, upon patch removal, PCD will be 
initiated due to UV light falling on skin in which there is residual drug in the 
epidermis/dermis that is still being absorbed.  
 A logical approach to this issue is to ensure that the skin, post-removal of the 
patch, is protected from UV-exposure for a period sufficient to ensure that 
ketoprofen levels in the cutaneous tissue have fallen to a level which is insufficient to 
trigger PCD.  How can this be determined?   
It is known that the risk of PCD when ketoprofen is taken orally is extremely 
low [26]. It follows that if the drug levels in skin after patch removal have decreased 
to below those observed when the drug is taken orally, then it should be safe to 
terminate protection of the treated site. Table 6 presents the plasma and skin 
concentrations of ketoprofen in man as a function of time after oral administration of 
a 50 mg immediate release tablet [27]. The maximum concentration attained in the 
skin was approximately 2 µg/g.  As this level poses minimal concern in terms of 
provoking PCD, it follows that this is the concentration to which residual ketoprofen 
in skin beneath the patch-treated site must decrease before UV exposure can be 
allowed to occur. 
 Measurements in human patients after using a ketoprofen patch showed that 
the average steady-state skin concentration of the drug was 109 (± 157) µg/g, with 
the maximum value observed being 521 µg/g. Assuming that the skin clearance half-
life from human skin is similar to that which has been measured in guinea pigs (i.e., 
about 1.5 days [28]), and that first-order kinetics are operative, it is straightforward 
to calculate that it would require ~12 days for this maximal level of ketoprofen in 
skin to decrease to 2 µg/g.  Conservatively, therefore, a 2-week period of 
photoprotection post-removal of a ketoprofen patch should minimise or eliminate any 
risk of drug-associated PCD1. 
 
                                                        
1 Of course, should it be shown that any of the ketoprofen photodegradation products have 
slower skin clearance than the drug itself, this period would need to be prolonged. 
Conclusions 
 The rationale for treating local subcutaneous inflammation with topical 
NSAIDs is logical and supported by experimental and clinical data; in addition, there 
is clear evidence for reduced adverse effects when using this approach (as compared 
with oral delivery).  The pharmacological activity and skin permeability of ketoprofen 
makes this drug an excellent choice for delivery via the skin.  Importantly, the known 
risk of ketoprofen-induced photocontact dermatitis is significantly less when using a 
topical ketoprofen patch than that for a gel product, most probably due to the 
protective role of the woven cloth backing.  Nonetheless, even when a patch is used, 
it is essential to protect the skin from UV exposure post-application to prevent 
photocontact dermatitis, most sensibly for a period of about 2 weeks. 
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Table 1: Serious adverse gastrointestinal (GI) and cardiovascular (CV) drug reactions to 
NSAIDsa in Europe from 2006 to 2012 following systemic and topical administration [6]. 
 
Adverse drug 
reaction (ADR) 
Systemic administration Topical administration 
GI disorders CV disorders GI disorders CV disorders 
Death 86 24 1 0 
Life-threatening 386 60 15 2 
Hospitalisation 1703 141 29 4 
Sequelae 13 3 1 0 
Other serious ADR 376 63 16 6 
aSpecifically, ketoprofen, diclofenac, indomethacin, ibuprofen, niflumic acid and piroxicam.  
Table 2: Incidence of ketoprofen-induced photocontact dermatitis according to spontaneous 
adverse drug reaction reports [12-14]. The frequencies represent the ratio of spontaneous 
photosensitivity events to the estimated number of patients treated. 
 
Formulation 
Estimated total 
number of treated 
patients (millions) 
Photocontact 
dermatitis 
Frequency (per 
million patients) 
Serious  Total    Serious Total 
Gel product in EU 
member states (2001-08) 
36.2 111 169 3.07 4.67 
Patch product in EU 
member states (2005-12) 
2.3 0 6 N/A 2.61 
Patch product in Japan 
(2001-2012)a 
474.5 29 1,560 0.06 3.29 
aUse of ketoprofen gel in Japan is relatively uncommon, with only an estimated 0.5 million patients 
being treated between 2001 and 2012; in this time, only a single non-serious case of PCD has been 
reported.  It should be noted that the marketed Japanese gel also contains a sunscreen. 
Table 3: Formation of the most common ketoprofen photodegradation products when a 
topical gel and a topical patch are exposed to UVA irradiation. 
 
Dosage form 
UVA 
exposure 
Ketoprofen 
Ketoprofen photodegradation products (%) 
KP-OH Ac-KP KP-Et 
    
Patch 
(-) 100.0 - - - 
(+) 97.0 - 0.1 - 
Gel 
(-) 100.0 - - - 
(+) 18.2 4.2 15.9 10.5 
 
 
Table 4: Photosensitisation potential of ketoprofen and its photodegradation products.  The 
scores in the right-hand columns reflect the sum of skin erythema and edema skin reactions 
assessed using Draize test criteria. 
 
Test 
Chemical 
Chemical Conc. (% w/v) Score (Mean ± S.D.) 
Induction Challenge 
Induction / UVA(-) 
Challenge / UVA(+) 
Induction / UVA(+) 
Challenge / UVA(+) 
24hr 48 hr 24hr 48hr 
KP 8 0.5 
2.0 
8.0 
0.0 0.0 1.1 ± 0.8 
1.9 ± 1.0 
2.4 ± 0.7 
1.8 ± 1.0 
2.9 ± 1.4 
3.5 ± 1.1 
KP-OH 8 0.5 
2.0 
8.0 
0.0 0.0 3.3 ± 1.4 
3.4 ± 1.2 
3.3 ± 1.0 
4.1 ± 1.1 
4.4 ± 0.9 
4.5 ± 0.8 
Ac-KP 8 0.5 
2.0 
8.0 
0.0 0.1 ± 0.4 
0.4 ± 0.5 
1.0 ± 0.9 
1.8 ± 1.4 
2.3 ± 1.2 
2.5 ± 1.3 
1.8 ± 1.4 
3.1 ± 1.6 
3.4 ± 1.4 
Et-KP 8 0.5 
2.0 
8.0 
0.0 0.0 3.3 ± 0.9 
3.8 ± 0.5 
4.5 ± 0.5 
3.8 ± 1.3 
4.5 ± 0.5 
5.0 ± 0.0 
 
Table 5: Sensitisation scores, at 24 and 48 hours post-challenge, determined (in the same 
way as those summarised in Table 4) in a photosensitisation test in guinea pigs treated with 
either a topical ketoprofen gel (Ketum) or a topical patch (KEPLAT).  
 
Formulation 
Score (Mean ± S.D.) 
24hr 48hr    
KP Gel (n = 6) 3.3 ± 1.2 3.5 ± 0.8 
KP Patch (n = 6) 0.5 ± 0.8 0.8 ± 1.2 
Table 6: Ketoprofen concentrations in plasma and skin after oral administration of a 50 mg 
immediate release tablet in man [27]. 
 
Time after oral 
dosing (hours) 
[Ketoprofen]plasma 
(μg/mL) 
[Ketoprofen]skin 
(μg/g) 
2 2.25 2.06 
6 0.24 0.34 
14 0.03 <LOQa 
  aBelow the limit of quantitation (LOQ).   
 
Figure Legends 
Figure 1: Ketoprofen pharmacokinetics (Cmax solid bars; AUC stippled bars) in man after (a) 
topical application of either a patch (Mohrus Tape, 20 mg, 70 cm2, n = 6)
 
or a gel (Sector gel 
[17], 300 mg, 900 cm2, n = 5), and (b) oral administration of either a standard tablet 
containing 100 mg (Orudis [15], n = 7) or a sustained release (SR) formulation of 150 mg 
(Orudis SR 150 [16], n = 8).  The Cmax and AUC (mean ± SD) post-application of the patch 
were 0.14 (± 0.02) mg/L and 2.45 (± 0.20) mg*hr/L, respectively. 
Figure 2: (A) Ketoprofen levels (mean ± SE; n = 6) 14 hours post-patch and oral 
administration in muscle, tendon and plasma.  (B) Temporal evolution of ketoprofen 
concentrations (mean ± SE) in muscle, tendon and plasma after drug delivery from a topical 
patch.  Significant differences (P < 0.05) are indicated by asterisks [24]. 
Figure 3: Photoallergic responses following a modified photo-LLNA
 
in mice treated with 
either a ketoprofen gel or a topical patch containing the drug.  Incorporations of 3H-
thymidine (Mean (± SD); n = 7) at the control, patch and gel-treated sites were 1736 (± 
903), 2722 (± 815), 8827 (± 1951) dpm/mouse, respectively. 
Figure 1: Ketoprofen pharmacokinetics (Cmax solid bars; AUC stippled bars) in man after (a) 
topical application of either a patch (Mohrus Tape, 20 mg, 70 cm2, n = 6)
 
or a gel (Sector gel 
[17], 300 mg, 900 cm2, n = 5), and (b) oral administration of either a standard tablet 
containing 100 mg (Orudis [15], n = 7) or a sustained release (SR) formulation of 150 mg 
(Orudis SR 150 [16], n = 8).  The Cmax and AUC (mean ± SD) post-application of the patch 
were 0.14 (± 0.02) mg/L and 2.45 (± 0.20) mg*hr/L, respectively. 
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 Figure 2: (A) Ketoprofen levels (mean ± SE; n = 6) 14 hours post-patch and oral 
administration in muscle, tendon and plasma.  (B) Temporal evolution of ketoprofen 
concentrations (mean ± SE) in muscle, tendon and plasma after drug delivery from a topical 
patch.  Significant differences (P < 0.05) are indicated by asterisks [24]. 
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in mice treated with 
either a ketoprofen gel or a topical patch containing the drug.  Incorporations of 3H-
thymidine (Mean (± SD); n = 7) at the control, patch and gel-treated sites were 1736 (± 
903), 2722 (± 815), 8827 (± 1951) dpm/mouse, respectively. 
 
 
 
